levonordefrin (Neo-Cobefrine) Report issue

Small molecule Approved FDA

Active Ingredient History

NOW
  • Now
Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It is administered in a pre-mixed solution with local anesthetics, such as mepivacaine or procaine.   NCATS

Chemistry

  • SMILES: C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1
  • InChIKey: GEFQWZLICWMTKF-CDUCUWFYSA-N
  • Mol. Mass: 183.2044
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

Combination drugs

( mepivacaine (carbocaine), levonordefrin (Neo-Cobefrine) - other names: arestocaine hydrochloride w/ levonordefrin, isocaine hydrochloride w/ levonordefrin, polocaine w/ levonordefrin, scandonest l )
|
( procaine merethoxylline, propoxycaine, levonordefrin (Neo-Cobefrine) )

Organizations (8)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Dental Care (approved 1960)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Anesthesia, Local (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue